108 related articles for article (PubMed ID: 7153406)
21. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial.
Fesq H; Lehmann J; Kontny A; Erdmann I; Theiling K; Rother M; Ring J; Cevc G; Abeck D
Br J Dermatol; 2003 Sep; 149(3):611-9. PubMed ID: 14510997
[TBL] [Abstract][Full Text] [Related]
22. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP
Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
[TBL] [Abstract][Full Text] [Related]
23. Iatrogenic hypercortisolism complicating triamcinolone acetonide injections in patients with HIV on ritonavir-boosted protease inhibitors.
Fessler D; Beach J; Keel J; Stead W
Pain Physician; 2012; 15(6):489-93. PubMed ID: 23159966
[TBL] [Abstract][Full Text] [Related]
24. Nonpigmenting solitary fixed drug eruption after skin testing and intra-articular injection of triamcinolone acetonide.
Sener O; Caliskaner Z; Yazicioglu K; Karaayvaz M; Ozangüç N
Ann Allergy Asthma Immunol; 2001 Mar; 86(3):335-6. PubMed ID: 11289335
[TBL] [Abstract][Full Text] [Related]
25. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
Chen M; Li X; Liu J; Han Y; Cheng L
J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
[TBL] [Abstract][Full Text] [Related]
26. [Post-corticoid atrophy].
Allemandou M
Ann Dermatol Venereol; 2001 Nov; 128(11):1267. PubMed ID: 11908181
[No Abstract] [Full Text] [Related]
27. Interdigital neuroma. Local cutaneous changes after corticosteroid injection.
Reddy PD; Zelicof SB; Ruotolo C; Holder J
Clin Orthop Relat Res; 1995 Aug; (317):185-7. PubMed ID: 7671475
[TBL] [Abstract][Full Text] [Related]
28. Major suppression of pro-alpha1(I) type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide.
Kauh YC; Rouda S; Mondragon G; Tokarek R; diLeonardo M; Tuan RS; Tan EM
J Am Acad Dermatol; 1997 Oct; 37(4):586-9. PubMed ID: 9344198
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography.
Aschoff R; Schmitt J; Knuschke P; Koch E; Bräutigam M; Meurer M
Exp Dermatol; 2011 Oct; 20(10):832-6. PubMed ID: 21771098
[TBL] [Abstract][Full Text] [Related]
30. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).
Kraus VB; Conaghan PG; Aazami HA; Mehra P; Kivitz AJ; Lufkin J; Hauben J; Johnson JR; Bodick N
Osteoarthritis Cartilage; 2018 Jan; 26(1):34-42. PubMed ID: 29024802
[TBL] [Abstract][Full Text] [Related]
31. Prolonged childhood Cushing's syndrome secondary to intralesional triamcinolone acetonide.
Teelucksingh S; Balkaran B; Ganeshmoorthi A; Arthur P
Ann Trop Paediatr; 2002 Mar; 22(1):89-91. PubMed ID: 11926057
[TBL] [Abstract][Full Text] [Related]
32. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid.
Lavker RM; Kaidbey K; Leyden JJ
J Am Acad Dermatol; 1992 Apr; 26(4):535-44. PubMed ID: 1597538
[TBL] [Abstract][Full Text] [Related]
33. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study.
Russell SJ; Sala R; Conaghan PG; Habib G; Vo Q; Manning R; Kivitz A; Davis Y; Lufkin J; Johnson JR; Kelley S; Bodick N
Rheumatology (Oxford); 2018 Dec; 57(12):2235-2241. PubMed ID: 30203101
[TBL] [Abstract][Full Text] [Related]
34. Intradermal triamcinolone treatment of psoriatic onychodystrophy.
Bedi TR
Dermatologica; 1977; 155(1):24-7. PubMed ID: 913743
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial.
Audren F; Erginay A; Haouchine B; Benosman R; Conrath J; Bergmann JF; Gaudric A; Massin P
Acta Ophthalmol Scand; 2006 Oct; 84(5):624-30. PubMed ID: 16965492
[TBL] [Abstract][Full Text] [Related]
36. Perilymphatic atrophy of the skin. A side effect of topical corticosteroid injection therapy.
Kikuchi I; Horikawa S
Arch Dermatol; 1974 Apr; 109(4):558-9. PubMed ID: 4819113
[No Abstract] [Full Text] [Related]
37. Dramatic hyperpigmentation of keloids after intralesional triamcinolone acetonide injection.
Koh WL; Lim SP
Dermatol Online J; 2015 May; 21(5):. PubMed ID: 26295862
[No Abstract] [Full Text] [Related]
38. [Transient disorders observed during injection of triamcinolone acetonide into keloids].
Mazurkiewicz W
Przegl Dermatol; 1980; 67(5):623-6. PubMed ID: 7455156
[No Abstract] [Full Text] [Related]
39. Comparative study on efficacy of a combination therapy of triamcinolone acetonide administration with and without vitrectomy for macular edema associated with branch retinal vein occlusion.
Hirano Y; Sakurai E; Yoshida M; Ogura Y
Ophthalmic Res; 2007; 39(4):207-12. PubMed ID: 17596753
[TBL] [Abstract][Full Text] [Related]
40. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision.
Shimura M; Yasuda K; Shiono T
Ophthalmology; 2006 Mar; 113(3):381-7. PubMed ID: 16458970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
